VIR BIOTECHNOLOGY INCVIR
ASignal's systematic analysis rates VIR as Neutral.
Reflects the latest available analysis · analyzed Sep 14, 2026
The case on VIR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth year-over-year (195.8%)
- High financial health score (0.9)
- Low debt-to-equity ratio (0.09x)
- High cash position ($532.73M) relative to debt ($93.27M)
- Current ratio of 6.04x indicates strong liquidity
- Negative MACD histogram suggesting weakening momentum
- Price below 20-day and 50-day moving averages
- Negative price momentum (-0.016)
- Negative profit, net, and gross margins
- Negative return on equity and return on assets
See the full verdict on VIR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VIR
Most investors never get a second opinion, let alone several. ASignal runs VIR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.